TopAlliance Biosciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, TopAlliance Biosciences sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
TopAlliance Biosciences: 2 sponsored US clinical trials, 1 recruiting.
TopAlliance Biosciences sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Unresectable Solid Tumor, with 1 trials.
Mid-pack sponsor footprint
TopAlliance Biosciences is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
NCT04137900
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
NCT03474640
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Therapeutic Areas
What is open in the TopAlliance Biosciences pipeline
1 recruiting of 2 indexed (50% open); 1 completed (50%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Advanced Unresectable Solid Tumor (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
TopAlliance Biosciences: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
TopAlliance Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this TopAlliance Biosciences page
2 registered trials is a research-attention snapshot, not an endorsement of TopAlliance Biosciences or any single study.
- 1 of TopAlliance Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Unresectable Solid Tumor is the condition TopAlliance Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Unresectable Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. TopAlliance Biosciences pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.